z-logo
open-access-imgOpen Access
BCL6 Is Required for Differentiation of Ig-Like Transcript 3-Fc–Induced CD8+ T Suppressor Cells
Author(s) -
ChihChao Chang,
George Vlad,
Vivette D. D’Agati,
Zhuoru Liu,
Qingyin Zhang,
Piotr Witkowski,
Ali Torkamani,
Michael B. Stokes,
Eric Ho,
Raffaello Cortesini,
Nicole SuciuFoca
Publication year - 2010
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.1001732
Subject(s) - cytotoxic t cell , cd8 , antigen presenting cell , pancreatic islets , microbiology and biotechnology , chemistry , biology , antigen , immunology , in vitro , islet , biochemistry , insulin , endocrinology
Ig-like transcript 3 (ILT3) is an inhibitory receptor expressed by tolerogenic dendritic cells. When human CD8(+) T cells are allostimulated in the presence of recombinant ILT3-Fc protein, they differentiate into antigenic specific T suppressor (Ts) cells that inhibit CD4 and CD8 T cell effector function both in vitro and in vivo. ILT3-Fc-induced CD8(+) Ts cells express high amounts of BCL6 that are crucial to their function. Knockdown of BCL6 from unprimed human T cells prevents their differentiation into Ts cells, whereas ex vivo overexpression of BCL6 converts CD8(+) T cells into Ts cells. NOD/SCID mice transplanted with human pancreatic islets and humanized by injection of human PBMCs tolerate the graft and develop BCL6(high) CD8(+) Ts cells when treated with ILT3-Fc before or after the onset of rejection. This indicates that ILT3-Fc acts through BCL6 and is a potent immunosuppressive agent for reversing the onset of allo- or possibly autoimmune attacks against pancreatic islets.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom